Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
NCT07037836Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of treprostinil in chronic obstructive pulmonary disease (COPD), hypoxemia. Started Sep 2025; status: recruiting.
02
Drugs
treprostinil
03
Conditions
chronic obstructive pulmonary disease (COPD)hypoxemia
Beyond the preview
Go deeper on NCT07037836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037836.